Acorda Therapeutics Inc: (NASD: ACOR)

$35.11

0.16 (0.46%)

Volume 63,182

Jun 19 11:35 AM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		34.68 - 35.36
	
		52wk Low - High
		21.33 - 40.87
	
		Previous Close
		34.95
	
		Avg. Volume
		292,778
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		1.42 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.52
	
		P/E (F1)
		143.63
	
		Current Year Est.
		0.24
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		112 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/7/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            143.63
                        
                            PEG Ratio
                            6.43
                        
                            Current Year Est.
                            0.24
                        
                            Current Quarter Estimate
                            0.10
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            0.43
                        
                            Expected Earnings Growth
                            22.33%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.   
Full ACOR Company Report

 Analyst Report on ACOR

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ACOR Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.10	0.07	0.24	1.01
Number of Estimates	2	2	3	3
Low Estimate	0.04	-0.04	-0.06	0.68
High Estimate	0.15	0.18	0.48	NA
Year Ago EPS	0.13	0.24	0.71	0.24
EPS Growth	-26.92%	-70.83%	-65.73%	313.70%

More ACOR Estimates

Average Earnings Estimates for ACOR

EPS Growth for ACOR

Industry Analysis

Name	Symbol	Previous Close
ACORDA THERAPT	ACOR	34.95
AETERNA ZENTARS	AEZS	1.90
BIOGEN IDEC INC	BIIB	210.80
MYRIAD GENETICS	MYGN	26.44
PROTALIX BIOTHR	PLX	5.08
ADDEX THERA LTD	ADDXF	3.95
AFFYMAX INC	AFFY	1.07
ALEXION PHARMA	ALXN	92.39
ALNYLAM PHARMA	ALNY	29.99
ANTHERA PHARMA	ANTH	0.58

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Additional Patent for Acorda's Ampyra

May 22, 2013

Acorda Incurs Loss, Maintains Guidance

May 06, 2013

Zacks Bull and Bear of the Day Highlights: Overstock.com, Titan Machinery, Acorda Therapeutics, Biogen Idec and Novartis

Apr 26, 2013

Acorda Initiates Study on rHIgM22

Apr 25, 2013

Acorda Reports Data on Epilepsy Drug

Mar 26, 2013

Acorda Presents GGF2 Data

Mar 08, 2013

Zacks Sell List Highlights: General Cable, Ternium, Acorda Therapeutics and Amsurg

Mar 01, 2013

Earnings Miss at Acorda

Feb 14, 2013

More ACOR Zacks Commentary

Financials

EPS TTM	0.43
Sales	306
Net Income	146
Price/Earnings	81.28
Price/Book	3.59
Price/Cash Flow	36.96
Price/Sales	4.63

More ACOR Financials

News

Acorda Therapeutics (ACOR) Trading Near $32.87 Support Level - Freshbrewedmedia

Jun 17, 2013

Ligand Pharmaceuticals is Among the Companies in the Biotechnology Industry With the Highest EBITDA Growth (LGND, ACOR, CPHD) - Financial News Network Online - News Corner

Jun 14, 2013

Stock Investors Sell Off Shares of Acorda Therapeutics, Down 1.2% - Financial News Network Online - Market Movers

Jun 13, 2013

Potential Acorda Therapeutics (ACOR) Trade Targets 15.44% Return - Freshbrewedmedia

Jun 11, 2013

5 Stocks Poised for Breakouts - TheStreet.com

Jun 7, 2013

Shares of Acorda Therapeutics Receive a Boost, Up 2.4% - Financial News Network Online - Market Movers

Jun 7, 2013

Acorda Therapeutics (ACOR) Could Break Through $33.94 Resistance Level - Freshbrewedmedia

Jun 5, 2013

Acorda Therapeutics receives US patent for treatment of multiple sclerosis - Datamonitor

Jun 4, 2013

See All News Stories on ACOR

Broker Recommendations

Current ABR	2.00
ABR (Last Week)	2.00
# of recs in ABR	9
Average Target Price	40.75
Industry Rank by ABR	112 out of 265
Rank in Industry	29 out of 154

More ACOR Broker Recommendations

Day Low - High	34.68 - 35.36
52wk Low - High	21.33 - 40.87
Previous Close	34.95
Avg. Volume	292,778
Industry	MED-BIOMED/GENE
Market Cap	1.42 B
Div - Yield	0.00 - 0.00
Beta	0.52
P/E (F1)	143.63
Current Year Est.	0.24
Quarterly Earnings ESP	NA

P/E (F1)	143.63
PEG Ratio	6.43
Current Year Est.	0.24
Current Quarter Estimate	0.10
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	08-06-2013
EPS Last Year	0.43
Expected Earnings Growth	22.33%

Username: Password:

Remember me [?]

Acorda Therapeutics Inc: (NASD: ACOR)

$35.11

0.16 (0.46%)

Volume 63,182

Jun 19 11:35 AM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description